Ivarmacitinib (SHR0302) is a small molecule drug and selective janus kinase 1 (JAK1) inhibitor. It is being developed for ulcerative colitis,[1] eczema, alopecia areata, and graft-versus-host disease.[2][3][4][5][6]
 | |
| Clinical data | |
|---|---|
| Other names | SHR0302 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C18H22N8O2S |
| Molar mass | 414.49 g·mol−1 |
References
edit- ^ Chen, Baili; Zhong, Jie; Li, Xiuling; Pan, Feng; Ding, Yijuan; Zhang, Yan; Chen, Hong; Liu, Fei; Zhang, Zhenyu; Zhang, Ling; Drozda, Rafal; Oliinyk, Oleksandr; Goh, Aik Han; Chen, Xiang; Sun, Xiang; Rubin, David T.; Sandborn, William J.; Chen, Minhu (December 2022). "Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study". Gastroenterology. 163 (6): 1555–1568. doi:10.1053/j.gastro.2022.08.007. ISSN 1528-0012. PMID 35963369.
- ^ Qiu, Huiying; Niu, Jiahua; Sun, Xi; Li, Huajun; Yang, Juan; Huang, Chongmei; Cai, Yu; Zhou, Kun; Tong, Yin; Wan, Liping; Song, Xianmin (15 November 2022). "Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT". Blood. 140 (Supplement 1): 7624. doi:10.1182/blood-2022-162148.
- ^ Li, Baoping; Li, Nanyang; Goh, Aik Han; Cao, Haifeng; Irwin, Min Wang; Tong, Xunian; Wang, Jingjing; Wu, Xiaojie; Zhang, Jing; Pu, Dan (9 May 2023). "A Phase I Study to Evaluate the Safety and Pharmacokinetics of SHR0302 Base Ointment in Healthy Adult Volunteers". Skin Pharmacology and Physiology. 36 (2): 76–86. doi:10.1159/000528739. ISSN 1660-5527. PMID 36580897.
- ^ Zhao, Yan; Zhang, Litao; Ding, Yangfeng; Tao, Xiaohua; Ji, Chao; Dong, Xiuqin; Lu, Jianyun; Wu, Liming; Wang, Rupeng; Lu, Qianjin; Goh, Aik Han; Liu, Rongjun; Zhang, Zhiguo; Zhang, Jianzhong (November 2021). "Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial". American Journal of Clinical Dermatology. 22 (6): 877–889. doi:10.1007/s40257-021-00627-2. PMC 8351769. PMID 34374027.
- ^ Zhou, Cheng; Yang, Xiumin; Yang, Bin; Yan, Guofu; Dong, Xiuqin; Ding, Yangfeng; Fan, Weixin; Li, Linfeng; Yang, Dingquan; Fang, Hong; Ji, Chao; Cheng, Hao; Zhang, Shoumin; Goh, Aik Han; Liu, Rongjun; Gu, Xiaoyu; Weng, Zaili; Foley, Peter; Sinclair, Rodney; Zhang, Jianzhong (November 2023). "A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 89 (5): 911–919. doi:10.1016/j.jaad.2023.02.063. PMID 37019385.
- ^ Ge, Xinyu; Ma, Sheng; Yan, Shu; Wu, Yali; Chen, Chong; Tang, Chongzhuang; Zhan, Yan; Bian, Yi-cong; Shen, Kai; Feng, Sheng; Gao, Xuehu; Zhong, Dafang; Zhang, Hua; Miao, Li-yan; Diao, Xing-xing (1 February 2023). "Mass balance study of [ 14 C]SHR0302, a selective and potent JAK1 inhibitor in humans". Xenobiotica. 53 (2): 69–83. doi:10.1080/00498254.2023.2176267. PMID 36745485.